(Total Views: 400)
Posted On: 02/27/2020 9:45:29 PM
Post# of 153908
Re: jacketsndisney #19631
“I think it is very possible that CYDY's management fails to fully capture all the potential of leronlimab for shareholders but they would have to really screw up to not capture at least 2-3 billion.”
Your statement above is very contradictory of itself. If CYDY can capture 2-3 billion from leronlimab, then a good portion of that 2-3 billion will be used to further investigate the potential of leronlimab in clinical trials (MS, etc.). And if CYDY captures 2-3 billion, the market cap of CYDY will be much higher and assist in raising more funds.
Also, cancer right now seems to be the best target for leronlimab and revenues from that will be much higher than 2-3 billion (just in breast cancer alone). HIV use to be, but with the BLA delay and the pausing of progress towards a mono phase 3, it appears HIV is second.
Your statement above is very contradictory of itself. If CYDY can capture 2-3 billion from leronlimab, then a good portion of that 2-3 billion will be used to further investigate the potential of leronlimab in clinical trials (MS, etc.). And if CYDY captures 2-3 billion, the market cap of CYDY will be much higher and assist in raising more funds.
Also, cancer right now seems to be the best target for leronlimab and revenues from that will be much higher than 2-3 billion (just in breast cancer alone). HIV use to be, but with the BLA delay and the pausing of progress towards a mono phase 3, it appears HIV is second.
(0)
(0)
